8 research outputs found

    Chaotic dynamics of falling disks

    Full text link
    The study of the motion of flat bodies falling in a viscous medium dates back at least to Newton(1) and Maxwell(2), and is relevant to problems in meteorology(3), sedimentology(4), aerospace engineering(1) and chemical engineering(5-8). More recent theoretical studies(9-12) have emphasized the role played by deterministic chaos, although many experimental studies(1,5-8,13,14) were performed before the development of such ideas. Here we report experimental observations of the dynamics of disks falling in water/glycerol mixtures. We find four distinct types of motion, which are mapped out in a 'phase diagram'. The apparently complex behaviour can be reduced to a series of one-dimensional maps, which display a discontinuity at the crossover from periodic to chaotic motion. This discontinuity leads to an unusual intermittency transition(15), not previously observed experimentally, between the two behaviours.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/62793/1/388252a0.pd

    Solid Particles Falling through Fluids

    No full text

    Sampling Methods

    No full text

    Ezetimibe added to statin therapy after acute coronary syndromes

    Get PDF
    BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit
    corecore